|
|
10100 Dr. Martin Luther King Jr. St. N.
St. Petersburg, FL 33716 USA
phone:561.789.8064
fax:727.568.1177
|
|
| Symbol |
Private |
| Founded |
2006 |
| Employees |
3 |
|
|
| www.clarosci.com
|
|
| Research Sector |
Medical Devices & Tech |
|
 |
| Summary Description |
| Biophotonics Research to Identify Micro-Organisms from Bodily Fluids. |
|
| Management |
| Tom McLain, M.B.A , Chief Executive Officer; Luis Garcia-Rubio, Ph.D., Co-Founder, President & Chief Scientific Officer; German LeParc, M.D, Co-Founder, Chief Medical Officer, Former CEO of Florida Blood Services; Bryant Moore, Ph.D., Vice President, Biotechnology &Technology Scouting Medtronic |
| |
|
|
| |
|
| Keywords |
| spectrometry, micro-organism, detection, bacteria, virus, parasites, bioparticulates, cells, pathogens, parasites, genetic, diseases, chemical, morphological, infection, biophotonics, characterization, spectroscopy, algorithms, |
|
|
|
| Description |
|
Claro Scientific has developed a unique optical diagnostic platform which delivers highly precise and quantitative information about the composition and character of micron and sub-micron particles, fluids, microorganisms, and cells. The company has rapidly advanced its core optical platform and proprietary algorithms through a combination of scientific and product development efforts, technology licenses, new patents, and proprietary know-how. Claro's technology is based on more than 30 years of peer-reviewed research and is the culmination of more than twenty years of collaborative academic, industrial, and biomedical partnerships by the Company's founder, Dr. Luis Garcia-Rubio. |
|
| Products / Services |
Based on more than 20 years of peer-reviewed research, Claro's patented technology is capable of quickly and accurately identifying pathologic changes in a sample using a simple-to-operate analyzer without requiring expensive reagents. The simplicity, cost-effectiveness, and accessibility of the product allows less highly trained professionals in less centralized clinical locations to quickly conduct a much broader array of diagnostic tests.
|
|
| Technology / Differentiation |
| Spectrophotometric techniques and methods, collectively known as biophotonics, can be used for the characterization of bioparticulates (including cells, platelets etc.) and therefore for the identification and detection of diseases. Claro's proprietary multidimensional spectroscopy techniques work by simultaneously measuring the optical attenuation resulting from the absorption, scattering, fluorescence and polarization of the light by the particles and suspending medium for a given sample. The digitally recorded data can be analyzed immediately and/or transmitted for archiving and for further analysis. |
|
| Market / Customers |
Claro's technology can be used to detect the presence of various pathogens, including bacteria, parasites, viral diseases that result in hematological and bleeding disorders and genetic diseases. The applications may be extended to morphological and chemical changes occurring in any bodily fluid as a result from infection. The global market for in-vitro diagnostics was valued at $38 billion in 2007, with continued growth expected.
|
|
| Status |
| The company's proprietary technology has received significant press coverage in technical and mainstream publications, ranging from the "Canadian Journal of Chemical Engineering" to the St. Petersburg Times. Claro expects to receive $113 million in revenue by 2010. |
|
|
|
|
|
|
|
Biotech & Specialty Pharma
Healthcare Services
Medical Devices & Tech
OneMedPlace Member
AdvaMed Members